| Citation: | Yang GAO, Zhao SUN, Chun-mei BAI. Application of Immune-checkpoint Inhibitors in Recurrent/Metastatic Nasopharyngeal Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 626-630. doi: 10.3969/j.issn.1674-9081.2020.05.021
|
Nasopharyngeal carcinoma is mainly associated with Epstein-Barr virus(EBV) infection. The treatment of early nasopharyngeal carcinoma has a good prognosis, but the treatment options for recurrent/metastatic nasopharyngeal carcinoma are limited and the prognosis is poor. In recent years, there have been extensive studies on immunotherapy in advanced nasopharyngeal carcinoma, among which immune-checkpoint inhibitors are effective and causing clinical concern. Programmed death-ligand 1 expression status, tumor mutation burden and circulating EBV-DNA level may be biomarkers for predicting the efficacy of immune-checkpoint inhibitors. The applications of immune-checkpoint inhibitors in recurrent/metastatic nasopharyngeal carcinoma will be reviewed in this article.
| [1] | Wei KR, Zheng RS, Zhang SW, et al. Nasopharyngeal carcinoma incidence and mortality in China, 2013[J]. Chin J Cancer, 2017,36:90. doi: 10.1186/s40880-017-0257-9 |
| [2] | Chua MLK, Wee JTS, Hui EP, et al. Nasopharyngeal carcinoma[J]. Lancet,2016,387:1012-1024. doi: 10.1016/S0140-6736(15)00055-0 |
| [3] | Ruuskanen M, Irjala H, Minn H, et al. Epstein-Barr virus and human papillomaviruses as favorable prognostic factors in nasopharyngeal carcinoma: A nationwide study in Finland[J]. Head Neck, 2019,41:349-357. http://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_wiley-blackwell-online-open_thesis/040004934268.html |
| [4] | Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis[J]. Lancet Oncol,2015,16:645-655. doi: 10.1016/S1470-2045(15)70126-9 |
| [5] | Yang L, Hong SD, Wang Y, et al. Development and External Validation of Nomograms for Predicting Survival in Nasopharyngeal Carcinoma Patients after Definitive Radiotherapy[J]. Sci Rep,2015,5:15638. doi: 10.1038/srep15638 |
| [6] | Perri F, Della VSG, Caponigro F, et al. Management of recurrent nasopharyngeal carcinoma: current perspectives[J]. Onco Targets Ther,2019,12:1583-1591. doi: 10.2147/OTT.S188148 |
| [7] | Le QT, Colevas AD, O'Sullivan B, et al. Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy[J]. J Natl Cancer Inst,2019,111:655-663. doi: 10.1093/jnci/djz044 |
| [8] | Larbcharoensub N, Mahaprom K, Jiarpinitnun C, et al. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma[J]. Am J Clin Oncol, 2018,41:1204-1210. doi: 10.1097/COC.0000000000000449 |
| [9] | Walker LSK, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses[J]. Nat Rev Immunol,2011,11:852-863. doi: 10.1038/nri3108 |
| [10] | Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies[J]. Clin Cancer Res,2013,19:3462-3473. doi: 10.1158/1078-0432.CCR-13-0855 |
| [11] | Fang WF, Zhang JW, Hong SD, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy[J]. Oncotarget,2014,5:12189-12202. doi: 10.18632/oncotarget.2608 |
| [12] | Hsu MC, Hsiao JR, Chang KC, et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma[J]. Mod Pathol,2010,23:1393-1403. doi: 10.1038/modpathol.2010.130 |
| [13] | Xiao M, Qi F, Chen X, et al. Functional polymorphism of cytotoxic T-lymphocyte antigen 4 and nasopharyngeal carcinoma susceptibility in a Chinese population[J]. Int J Immunogenet, 2010,37:27-32. doi: 10.1111/j.1744-313X.2009.00888.x |
| [14] | Hsu C, Lee SH, Ejadi S, et al. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study[J]. J Clin Oncol,2017,35:4050-4056. doi: 10.1200/JCO.2017.73.3675 |
| [15] | Ma B, Lim WT, Goh BC, et al. Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)[J]. J Clin Oncol, 2018,36:1412-1418. doi: 10.1200/JCO.2017.77.0388 |
| [16] | Fang WF, Yang YP, Ma YX, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials[J]. Lancet Oncol,2018,19:1338-1350. doi: 10.1016/S1470-2045(18)30495-9 |
| [17] | Zhou YJ, Shi DB, Miao JJ, et al. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load[J]. Sci Rep,2017,7:43627. doi: 10.1038/srep43627 |
| [18] | Fang WF, Zhang JW, Hong SD, et al. EBV-driven LMP1 and IFN-gamma up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy[J]. Oncotarget, 2014,5:12189-12202. doi: 10.18632/oncotarget.2608 |
| [19] | Ferris RL, Blumenschein GJ, Fayette J, et al. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression[J]. Oral Oncol,2018,81:45-51. doi: 10.1016/j.oraloncology.2018.04.008 |
| [20] | Harrington KJ, Ferris RL, Blumenschein GJ, et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial[J]. Lancet Oncol,2017,18:1104-1115. doi: 10.1016/S1470-2045(17)30421-7 |
| [21] | Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial[J]. Lancet Oncol, 2016,17:956-965. doi: 10.1016/S1470-2045(16)30066-3 |
| [22] | Liu MB, Han SJ, Zheng B, et al. Cost-Effectiveness Analysis Of Pembrolizumab In The Treatment Of Advanced Recurrent Metastatic Head And Neck Squamous Cell Carcinoma In China And The United States[J]. Cancer Manag Res,2019,11:9483-9493. doi: 10.2147/CMAR.S226243 |
| [23] | Cohen EEW, Soulieres D, Le Tourneau C, et al. Pembroli-zumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study[J]. Lancet, 2019,393:156-167. doi: 10.1016/S0140-6736(18)31999-8 |
| [24] | Kim KY, Le QT, Yom SS, et al. Clinical Utility of Epstein-Barr Virus DNA Testing in the Treatment of Nasopharyngeal Carcinoma Patients[J]. Int J Radiat Oncol Biol Phys,2017,98:996-1001. doi: 10.1016/j.ijrobp.2017.03.018 |
| [25] | Wang WY, Lin TY, Twu CW, et al. Long-term clinical outcome in nasopharyngeal carcinoma patients with post-radiation persistently detectable plasma EBV DNA[J]. Oncotarget,2016,7:42608-42616. http://www.ncbi.nlm.nih.gov/pubmed/27191654 |
| [26] | Chan ATC, Hui EP, Ngan RKC, et al. Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial[J]. J Clin Oncol,2018.doi: 10.1200/JCO.2018.77.7847. |
| [27] | Johnson DB, Frampton GM, Rioth MJ, et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade[J]. Cancer Immunol Res, 2016,4:959-967. doi: 10.1158/2326-6066.CIR-16-0143 |
| [28] | Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science,2015,348:124-128. doi: 10.1126/science.aaa1348 |
| [29] | Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial[J]. Lancet,2016,387:1909-1920. doi: 10.1016/S0140-6736(16)00561-4 |
| [30] | Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J]. Nat Genet,2019,51:202-206. doi: 10.1038/s41588-018-0312-8 |
| [31] | Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival[J]. Genome Res,2014,24:743-750. doi: 10.1101/gr.165985.113 |
| [32] | Cesano A, Warren S. Bringing the next Generation of Immuno-Oncology Biomarkers to the Clinic[J]. Biomedicines,2018,6:14. doi: 10.3390/biomedicines6010014 |
Supported by:
Beijing Renhe Information Technology Co. Ltd
Submit
Review
Office
Email Alert
RSS
DownLoad: